272 related articles for article (PubMed ID: 37398703)
21. Axillary response according to neoadjuvant single or dual human epidermal growth factor receptor 2 (HER2) blockade in clinically node-positive, HER2-positive breast cancer.
Cha C; Ahn SG; Kim D; Lee J; Park S; Bae SJ; Kim JY; Park HS; Park S; Kim SI; Park BW; Jeong J
Int J Cancer; 2021 Oct; 149(8):1585-1592. PubMed ID: 34213778
[TBL] [Abstract][Full Text] [Related]
22. Efficacy and safety of HER2 inhibitors in combination with or without pertuzumab for HER2-positive breast cancer: a systematic review and meta-analysis.
Chen S; Liang Y; Feng Z; Wang M
BMC Cancer; 2019 Oct; 19(1):973. PubMed ID: 31638935
[TBL] [Abstract][Full Text] [Related]
23. Efficacy, Safety, and Tolerability of Pertuzumab, Trastuzumab, and Docetaxel for Patients With Early or Locally Advanced ERBB2-Positive Breast Cancer in Asia: The PEONY Phase 3 Randomized Clinical Trial.
Shao Z; Pang D; Yang H; Li W; Wang S; Cui S; Liao N; Wang Y; Wang C; Chang YC; Wang H; Kang SY; Seo JH; Shen K; Laohawiriyakamol S; Jiang Z; Li J; Zhou J; Althaus B; Mao Y; Eng-Wong J
JAMA Oncol; 2020 Mar; 6(3):e193692. PubMed ID: 31647503
[TBL] [Abstract][Full Text] [Related]
24. Assessment of a Genomic Assay in Patients With ERBB2-Positive Breast Cancer Following Neoadjuvant Trastuzumab-Based Chemotherapy With or Without Pertuzumab.
Bueno-Muiño C; Echavarría I; López-Tarruella S; Roche-Molina M; Del Monte-Millán M; Massarrah T; Jerez Y; Ayala de la Peña F; García-Sáenz JÁ; Moreno F; Rodríguez-Lescure Á; Malón-Giménez D; Ballesteros García AI; Marín-Aguilera M; Galván P; Brasó-Maristany F; Waks AG; Tolaney SM; Mittendorf EA; Vivancos A; Villagrasa P; Parker JS; Perou CM; Paré L; Villacampa G; Prat A; Martín M
JAMA Oncol; 2023 Jun; 9(6):841-846. PubMed ID: 37103916
[TBL] [Abstract][Full Text] [Related]
25. Event-Free Survival in Patients with Early HER2-Positive Breast Cancer with a Pathological Complete Response after HER2-Targeted Therapy: A Pooled Analysis.
Swain SM; Macharia H; Cortes J; Dang C; Gianni L; Hurvitz SA; Jackisch C; Schneeweiss A; Slamon D; Valagussa P; du Toit Y; Heinzmann D; Knott A; Song C; Cortazar P
Cancers (Basel); 2022 Oct; 14(20):. PubMed ID: 36291835
[TBL] [Abstract][Full Text] [Related]
26. Neoadjuvant therapy for early human epidermal growth factor receptor 2 positive breast cancer in China: A multicenter real-world study (CSBrS-015).
Cheng Y; Xiang H; Xin L; Duan X; Liu Y;
Chin Med J (Engl); 2022 Oct; 135(19):2311-2318. PubMed ID: 36535009
[TBL] [Abstract][Full Text] [Related]
27. Cost-effectiveness analysis of neoadjuvant pertuzumab and trastuzumab therapy for locally advanced, inflammatory, or early HER2-positive breast cancer in Canada.
Attard CL; Pepper AN; Brown ST; Thompson MF; Thuresson PO; Yunger S; Dent S; Paterson AH; Wells GA
J Med Econ; 2015 Mar; 18(3):173-88. PubMed ID: 25347449
[TBL] [Abstract][Full Text] [Related]
28. Dual HER2-blockade with pertuzumab and trastuzumab in HER2-positive early breast cancer: a subanalysis of data from the randomized phase III GeparSepto trial.
Loibl S; Jackisch C; Schneeweiss A; Schmatloch S; Aktas B; Denkert C; Wiebringhaus H; Kümmel S; Warm M; Paepke S; Just M; Hanusch C; Hackmann J; Blohmer JU; Clemens M; Dan Costa S; Gerber B; Engels K; Nekljudova V; von Minckwitz G; Untch M;
Ann Oncol; 2017 Mar; 28(3):497-504. PubMed ID: 27831502
[TBL] [Abstract][Full Text] [Related]
29. PR status is a more decisive factor in efficacy of adding pertuzumab into neoadjuvant therapy for HER2-positive and lymph node-positive breast cancer than ER status: a real-world retrospective study in China.
Liu X; Liu Z; Li C; Song X; Wang X; Li S; Yu Z
World J Surg Oncol; 2023 Sep; 21(1):296. PubMed ID: 37723497
[TBL] [Abstract][Full Text] [Related]
30. Chemotherapy de-escalation using an
Pérez-García JM; Gebhart G; Ruiz Borrego M; Stradella A; Bermejo B; Schmid P; Marmé F; Escrivá-de-Romani S; Calvo L; Ribelles N; Martinez N; Albacar C; Prat A; Dalenc F; Kerrou K; Colleoni M; Afonso N; Di Cosimo S; Sampayo-Cordero M; Malfettone A; Cortés J; Llombart-Cussac A;
Lancet Oncol; 2021 Jun; 22(6):858-871. PubMed ID: 34019819
[TBL] [Abstract][Full Text] [Related]
31. Effect of pertuzumab, trastuzumab, and docetaxel in HER2-positive metastatic breast cancer: A meta-analysis
.
Tian T; Ye J; Zhou S
Int J Clin Pharmacol Ther; 2017 Sep; 55(9):720-727. PubMed ID: 28737130
[TBL] [Abstract][Full Text] [Related]
32. Efficacy and safety of neoadjuvant pertuzumab and trastuzumab in women with locally advanced, inflammatory, or early HER2-positive breast cancer (NeoSphere): a randomised multicentre, open-label, phase 2 trial.
Gianni L; Pienkowski T; Im YH; Roman L; Tseng LM; Liu MC; Lluch A; Staroslawska E; de la Haba-Rodriguez J; Im SA; Pedrini JL; Poirier B; Morandi P; Semiglazov V; Srimuninnimit V; Bianchi G; Szado T; Ratnayake J; Ross G; Valagussa P
Lancet Oncol; 2012 Jan; 13(1):25-32. PubMed ID: 22153890
[TBL] [Abstract][Full Text] [Related]
33. Real-world experience with pertuzumab and trastuzumab combined with chemotherapy in neoadjuvant treatment for patients with early-stage HER2-positive breast cancer: the NEOPERSUR study.
Falcón González A; Cruz Jurado J; Llabrés Valenti E; Urbano Cubero R; Álamo de la Gala MC; Martínez Guisado MA; Álvarez Ambite R; Rodríguez González CJ; Amérigo Góngora M; Rodríguez Pérez L; López Álvarez P; Sánchez Rovira P; González Flores E; Henao Carrasco F; Bayo Calero J; Valero Arbizu M; Quílez Cutillas A; Salvador Boffil J; Rubio Pérez E; Ruiz-Borrego M
Clin Transl Oncol; 2024 Mar; ():. PubMed ID: 38538968
[TBL] [Abstract][Full Text] [Related]
34. Pertuzumab, trastuzumab, and docetaxel for HER2-positive metastatic breast cancer (CLEOPATRA): end-of-study results from a double-blind, randomised, placebo-controlled, phase 3 study.
Swain SM; Miles D; Kim SB; Im YH; Im SA; Semiglazov V; Ciruelos E; Schneeweiss A; Loi S; Monturus E; Clark E; Knott A; Restuccia E; Benyunes MC; Cortés J;
Lancet Oncol; 2020 Apr; 21(4):519-530. PubMed ID: 32171426
[TBL] [Abstract][Full Text] [Related]
35. Dual HER2 Blockade in Neoadjuvant Treatment of HER2+ Breast Cancer: A Meta-Analysis and Review.
Wang C; Chen J; Xu X; Hu X; Kong D; Liang G; Wang X
Technol Cancer Res Treat; 2020; 19():1533033820960721. PubMed ID: 32990165
[TBL] [Abstract][Full Text] [Related]
36. Pertuzumab in HER2-positive breast cancer.
Sendur MA; Aksoy S; Altundag K
Curr Med Res Opin; 2012 Oct; 28(10):1709-16. PubMed ID: 22953713
[TBL] [Abstract][Full Text] [Related]
37. Tumor-infiltrating lymphocytes in patients with HER2-positive breast cancer treated with neoadjuvant chemotherapy plus trastuzumab, lapatinib or their combination: A meta-analysis of randomized controlled trials.
Solinas C; Ceppi M; Lambertini M; Scartozzi M; Buisseret L; Garaud S; Fumagalli D; de Azambuja E; Salgado R; Sotiriou C; Willard-Gallo K; Ignatiadis M
Cancer Treat Rev; 2017 Jun; 57():8-15. PubMed ID: 28525810
[TBL] [Abstract][Full Text] [Related]
38. Toxicity of dual HER2-blockade with pertuzumab added to anthracycline versus non-anthracycline containing chemotherapy as neoadjuvant treatment in HER2-positive breast cancer: The TRAIN-2 study.
van Ramshorst MS; van Werkhoven E; Honkoop AH; Dezentjé VO; Oving IM; Mandjes IA; Kemper I; Smorenburg CH; Stouthard JM; Linn SC; Sonke GS;
Breast; 2016 Oct; 29():153-9. PubMed ID: 27498129
[TBL] [Abstract][Full Text] [Related]
39. Cardiac Safety of Dual Anti-HER2 Therapy in the Neoadjuvant Setting for Treatment of HER2-Positive Breast Cancer.
Yu AF; Singh JC; Wang R; Liu JE; Eaton A; Oeffinger KC; Steingart RM; Hudis CA; Dang CT
Oncologist; 2017 Jun; 22(6):642-647. PubMed ID: 28341761
[TBL] [Abstract][Full Text] [Related]
40. Different Pathological Complete Response Rates According to PAM50 Subtype in HER2+ Breast Cancer Patients Treated With Neoadjuvant Pertuzumab/Trastuzumab vs. Trastuzumab Plus Standard Chemotherapy: An Analysis of Real-World Data.
Díaz-Redondo T; Lavado-Valenzuela R; Jimenez B; Pascual T; Gálvez F; Falcón A; Alamo MDC; Morales C; Amerigo M; Pascual J; Sanchez-Muñoz A; González-Guerrero M; Vicioso L; Laborda A; Ortega MV; Perez L; Fernandez-Martinez A; Chic N; Jerez JM; Alvarez M; Prat A; Ribelles N; Alba E
Front Oncol; 2019; 9():1178. PubMed ID: 31750258
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]
